Tirzepatide cut progression from prediabetes to diabetes by over 90%
Gokhan notes that tirzepatide (a GLP-1/GIP drug) cut the chance of progressing from prediabetes to diabetes by over 90%, linking a ScienceAlert report of a 94% reduction in adults with obesity or overweight and prediabetes.



